Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Company Details
- Employees
- 106
- Founded
- -
- Address
- 110 East 59th Street,
- Phone
- 212-883-0200
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- royaltypharma.com
- HQ
- New York, New York
Royalty Pharma Questions
Royalty Pharma's helpline number is 212-883-0200
Royalty Pharma's website is royaltypharma.com
Royalty Pharma's LinkedIn profile is https://www.linkedin.com/company/royalty-pharma
Royalty Pharma has
106 employees.
View email and phone details for 106
employees at Royalty Pharma.
Royalty Pharma's industry is
Biotechnology Research
Royalty Pharma's top competitors are
Tourmaline Bio,
Sciegen Pharmaceuticals Inc,
Dianthus Therapeutics, Inc.,
Anavex Life Sciences,
Biospherix, Llc,
Gilgamesh Pharmaceuticals,
Nuvation Bio,
Immunic Therapeutics,
Envisagenics,
Lexeo Therapeutics.
Royalty Pharma's categories are Biotechnology Research
Royalty Pharma's founding year is 1996
